Evolution of Therapeutic Interventions in Ischemic Heart Disease: A Global Perspective

Authors

  • Jinzhuo Yu
  • Jinzhuo Yu
  • Xiaolong Guo
  • Chuanhui Li

DOI:

https://doi.org/10.62051/ijphmr.v1n3.06

Keywords:

Ischemic heart disease, Treatment plan

Abstract

Ischemic heart disease (IHD) remains a leading cause of morbidity and mortality worldwide, significantly burdening healthcare systems. As populations age and lifestyles increasingly adopt unhealthy habits, the incidence of IHD continues to rise, prompting advancements in therapeutic interventions. According to the World Health Organization (WHO), IHD is a leading cause of death globally, accounting for millions of deaths each year. The continuous evolution of treatment modalities, from pharmacotherapy to surgical interventions, reflects the ongoing quest to enhance patient outcomes and manage the disease more effectively. Despite advancements, significant disparities exist in IHD treatment across different regions. Developed countries typically have access to advanced medical technologies and resources, offering higher standards of care. In contrast, developing nations often face challenges such as inadequate medical infrastructure and uneven healthcare quality, leading to suboptimal treatment outcomes for IHD patients. This paper aims to provide a comprehensive overview of the evolution of IHD therapeutic interventions from a global perspective, highlighting significant milestones and comparing treatment practices across various countries. By examining the application and effectiveness of different treatment methods, we seek to identify strengths and weaknesses in IHD management worldwide, offering insights for future improvements in global healthcare strategies.

References

Bibault, J.-E., Chaix, B., Nectoux, P., Pienkowski, A., Guillemassé, A., Brouard, B., & Giraud, P. (2020). Healthcare ex machina: Are conversational agents ready for prime time in oncology? Clinical Cancer Informatics, 4, 1–9.

Kelly K L. Beta blockers in hypertension: a review [J]. American Journal of Hospital Pharmacy, 1976, 33(12): 1284-1290.

Rural Health Information Hub. (2021). Rural health disparities.

Favaloro, R. G. (1969). Saphenous vein autograft replacement of severe segmental coronary artery occlusion: Operative technique. Annals of Thoracic Surgery, 7(3), 196–201.

Fischman D L, Leon M B, Baim D S, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease [J]. New England Journal of Medicine, 1994, 331(8): 496-501.

Brunetti N D, Scalvini S, Acquistapace F, et al. Telemedicine for cardiovascular disease continuum: a position paper from the Italian Society of Cardiology Working Group on Telecardiology and Informatics [J]. International journal of cardiology, 2015, 184: 452-458.

Harskamp, R. E., Lopes, R. D., Baisden, C. E., de Winter, R. J., Alexander, J. H., & Saphenous Vein Graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators. (2013). Saphenous vein graft failure after coronary artery bypass surgery: Pathophysiology, management, and future directions. Annals of Surgery, 257(5), 824–833.

Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., ... & Guyton, R. A. (2016). 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: An update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation, 133(11), 1135–1147.

Morice, M. C., Serruys, P. W., Sousa, J. E., Fajadet, J., Ban Hayashi, E., Perin, M., ... & Zoli, V. (2002). A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. New England Journal of Medicine, 346(23), 1773–1780.

Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation [J]. European heart journal, 2003, 24(1): 28-66.

Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., ... & Wilson, P. W. (2014). 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 129(25 Suppl 2), S1–S45.

Yusuf, S., Reddy, S., Ôunpuu, S., & Anand, S. (2001). Global burden of cardiovascular diseases: Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation, 104(22), 2746–2753.

Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study [J]. The lancet, 2004, 364(9438): 937-952.

Downloads

Published

26-06-2024

Issue

Section

Articles

How to Cite

Yu, J., Yu, J., Guo, X., & Li, C. (2024). Evolution of Therapeutic Interventions in Ischemic Heart Disease: A Global Perspective. International Journal of Public Health and Medical Research, 1(3), 32-35. https://doi.org/10.62051/ijphmr.v1n3.06